pharmaphorum

APRIL 23, 2021

The alliance is based on Obsidian’s cytoDRIVE platform, which uses already approved small-molecule drugs alongside gene-editing medicines to control the expression of protein from a gene sequence. For example, adding a small-molecule might stabilise the medicine, allowing levels of the target protein to increase. .

Gene Editing 52

Gene Editing Genetics Drugs Gene 52

Drug Discovery World

FEBRUARY 5, 2024

Brian Gladsden, CEO, Mosaic Therapeutics “The industry has already made tremendous strides in targeted drug discovery in oncology, particularly as the industry moves further away from simply looking at tumour histology and relying more on cancer gene sequencing. In the past 10 years, immunotherapy trials have increased by 430%.

Research 113

Research Drug Delivery Systems Gene Sequencing Trials 113

Pharmaceutical Technology

MAY 26, 2023

As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA. Biopharmaceutical companies like Pfizer and Lonza have announced licensing agreements to use the doggybone in their own respective research.

DNA 130

DNA Manufacturing Gene Therapy Gene 130